Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

5.655 +0.075 (+1.34%)
Streaming Delayed Price Updated: 12:50 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. 
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT 
From Recursion Pharmaceuticals
Via GlobeNewswire
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Merging with a former rival will bolster its capabilities. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
We'll know a little more about the biotech's prospects in a year and a half. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Efficiency in core processes is set to increase substantially due to AI. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Operational complementarities expected to yield annual synergies of approximately $100 million 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Is Recursion Pharmaceuticals a Millionaire-Maker?
It's likely to experience a lot of growth. 
Via The Motley Fool
99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks
Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
25 Best Artificial Intelligence Stocks to Buy Right Now
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
This article identifies the 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Millionaire-Maker Artificial Intelligence (AI) Stocks
For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
Is Recursion Pharmaceuticals Stock a Buy?
The company is ambitious and exploring exciting areas, but it's still early in the game. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.